Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback